1. Medtech Insight
  2. >>Device Area

Orthopedic Roundup: Q2 Results Show Recovery In Elective Procedures; COVID-19 Uncertainties Remain

 
• By Marion Webb

The major orthopedic device makers saw sharp sales declines during the second quarter and remain cautiously optimistic for the rest of 2020.

Hip joint and bone anatomy concept photo. Doctor points to anatomy model of hip joint and pelvis bone with ligaments where localized diseases such as dysplasia, fracture, osteoarthritis or replacement

Three of the major four orthopedic device companies beat analyst expectations in the second quarter of 2020 as procedure volumes began recovering. While expectations remain high for orthopedics makers that procedure volumes will continue its upward trend, the ongoing COVID-19 pandemic creates a lot of uncertainties.

Zimmer Biomet Holdings, Inc. was the last of the four big orthopedics companies to report second-quarter earnings on 4 August, but like its competitors, it beat analysts’ expectations after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.